X-Aptamer Selection and Validation.

Aptamers and second generation analogs, such as X-Aptamers (XAs), SOMAmers, locked nucleic acids (LNAs), and others are increasingly being used for molecular pathway targeting, biomarker discovery, or disease diagnosis by interacting with protein targets on the surface of cells or in solution. Such targeting is being used for imaging, diagnostic evaluation, interference of protein function, or delivery of therapeutic agents. Selection of aptamers using the original SELEX method is cumbersome and time-consuming, often requiring 10-15 rounds of selection, and provides aptamers with a limited number of functional groups, namely four bases of DNA or RNA, although newer SELEX methods have increased this diversity. In contrast, X-Aptamers provide an unlimited number of functional groups and thus are superior targeting agents. Here, we discuss the X-Aptamer selection process.

[1]  D. Volk,et al.  An ab initio study of phosphorothioate and phosphorodithioate interactions with sodium cation , 2002 .

[2]  M. Ferrari,et al.  Bone marrow endothelium-targeted therapeutics for metastatic breast cancer. , 2014, Journal of controlled release : official journal of the Controlled Release Society.

[3]  Michael Blank,et al.  Aptamer Selection Technology and Recent Advances , 2015, Molecular therapy. Nucleic acids.

[4]  Toshimasa Ishida,et al.  Synthesis of 2′-O,4′-C-methyleneuridine and -cytidine. Novel bicyclic nucleosides having a fixed C3, -endo sugar puckering , 1997 .

[5]  J. Szostak,et al.  In vitro selection of RNA molecules that bind specific ligands , 1990, Nature.

[6]  D. Gorenstein,et al.  Delivery of double-stranded DNA thioaptamers into HIV-1 infected cells for antiviral activity. , 2006, Biochemical and biophysical research communications.

[7]  A. Barrett,et al.  Selection of Thioaptamers for Diagnostics and Therapeutics , 2006, Annals of the New York Academy of Sciences.

[8]  J. Hope,et al.  Characterization of 2′-Fluoro-RNA Aptamers That Bind Preferentially to Disease-associated Conformations of Prion Protein and Inhibit Conversion* , 2003, Journal of Biological Chemistry.

[9]  H. Rui,et al.  Blocking the adhesion cascade at the premetastatic niche for prevention of breast cancer metastasis. , 2015, Molecular therapy : the journal of the American Society of Gene Therapy.

[10]  Andrew D Ellington,et al.  Construction and selection of bead-bound combinatorial oligonucleoside phosphorothioate and phosphorodithioate aptamer libraries designed for rapid PCR-based sequencing. , 2002, Nucleic acids research.

[11]  D. Volk,et al.  Solution structure and design of dithiophosphate backbone aptamers targeting transcription factor NF-κB , 2002 .

[12]  D. Gorenstein,et al.  Aptamers containing thymidine 3'-O-phosphorodithioates: synthesis and binding to nuclear factor-kappaB. , 1999, Bioorganic & medicinal chemistry letters.

[13]  Jonathan Richards,et al.  Electrochemical aptamer scaffold biosensors for detection of botulism and ricin toxins. , 2015, Chemical communications.

[14]  L. Gold,et al.  Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. , 1990, Science.

[15]  Poul Nielsen,et al.  LNA (Locked Nucleic Acids): Synthesis of the adenine, cytosine, guanine, 5-methylcytosine, thymine and uracil bicyclonucleoside monomers, oligomerisation, and unprecedented nucleic acid recognition , 1998 .

[16]  V. Henrich,et al.  Nano-SPRi Aptasensor for the Detection of Progesterone in Buffer , 2016, Scientific Reports.

[17]  S. Tope,et al.  Aptamers as therapeutics , 2013 .

[18]  M. Ferrari,et al.  Combinatorial selection of DNA thioaptamers targeted to the HA binding domain of human CD44. , 2010, Biochemistry.

[19]  Mauro Ferrari,et al.  E‐Selectin‐Targeted Porous Silicon Particle for Nanoparticle Delivery to the Bone Marrow , 2011, Advanced materials.

[20]  D. Gorenstein,et al.  A chemical approach for site-specific identification of NMR signals from protein side-chain NH3+ groups forming intermolecular ion pairs in protein–nucleic acid complexes , 2015, Journal of biomolecular NMR.

[21]  S. Watowich,et al.  Combinatorial selection of a RNA thioaptamer that binds to Venezuelan equine encephalitis virus capsid protein , 2007, FEBS letters.

[22]  Eun Jeong Cho,et al.  Applications of aptamers as sensors. , 2009, Annual review of analytical chemistry.

[23]  Xin Li,et al.  Identification of Thioaptamer Ligand against E-Selectin: Potential Application for Inflamed Vasculature Targeting , 2010, PloS one.

[24]  D. Volk,et al.  X-aptamers: a bead-based selection method for random incorporation of druglike moieties onto next-generation aptamers for enhanced binding. , 2012, Biochemistry.

[25]  Yoon-Sik Lee,et al.  RNA aptamers: a review of recent trends and applications. , 2013, Advances in biochemical engineering/biotechnology.

[26]  M. Ferrari,et al.  Thioaptamer Conjugated Liposomes for Tumor Vasculature Targeting , 2010, Oncotarget.

[27]  D. Volk,et al.  Thioaptamers targeting dengue virus type-2 envelope protein domain III. , 2014, Biochemical and biophysical research communications.

[28]  E. Timofeev,et al.  The Toolbox for Modified Aptamers , 2016, Molecular Biotechnology.

[29]  R A Bendele,et al.  Derivation of RNA aptamer inhibitors of human complement C5. , 1999, Immunopharmacology.

[30]  Y. Zu,et al.  Oligonucleotide Aptamers: New Tools for Targeted Cancer Therapy , 2014, Molecular therapy. Nucleic acids.

[31]  Bruce A Luxon,et al.  Combinatorial selection of a single stranded DNA thioaptamer targeting TGF-beta1 protein. , 2008, Bioorganic & medicinal chemistry letters.

[32]  Jeffrey T. Chang,et al.  Aptaligner: Automated Software for Aligning Pseudorandom DNA X-Aptamers from Next-Generation Sequencing Data , 2014, Biochemistry.